ÐÂÎÅ×ÊѶ
Ò»Æðѧϰ£ºÈçºÎʹÓÃ4¿îоƬ·¢±íһƪJCI (IF: 12.282)
- ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
- ×÷Õߣºk8¿·¢(Öйú)
- À´Ô´£º
¡¾¸ÅÒªÃèÊö¡¿ÉúÎïоƬ¼¼ÊõÊÇͨ¹ý»¯Ñ§Å¼ÁªµÄ·½·¨£¬½«ÉúÎï·Ö×Ó£¨¹ÑºËÜÕËá¡¢¿¹Ìå¡¢¿¹Ô¡¢×éÖ¯µÈ£©¸ßÃܶȹÌ×ÅÓÚ¹èƬ»ò´ÅÖé±íÃæµÄÉúÎï¼ì²â¼¼Êõ£¬°üº¬£º»ùÒòоƬ¡¢µ°°×ÖÊоƬ¡¢¿¹ÌåоƬ¡¢×é֯оƬµÈ¼Ò×å³ÉÔ±¡£ÓÉÓھ߱¸¸ßͨÁ¿¼ì²âµÄÌØÐÔ£¬ÉúÎïоƬ¿ÉÒÔΪÉúÎïҽѧÁìÓòµÄÑо¿ÈËÔ±Ìṩ¹ã·º¶ø¿É¿¿Ñо¿Êý¾Ý¡£
Ò»Æðѧϰ£ºÈçºÎʹÓÃ4¿îоƬ·¢±íһƪJCI (IF: 12.282)
¡¾¸ÅÒªÃèÊö¡¿ÉúÎïоƬ¼¼ÊõÊÇͨ¹ý»¯Ñ§Å¼ÁªµÄ·½·¨£¬½«ÉúÎï·Ö×Ó£¨¹ÑºËÜÕËá¡¢¿¹Ìå¡¢¿¹Ô¡¢×éÖ¯µÈ£©¸ßÃܶȹÌ×ÅÓÚ¹èƬ»ò´ÅÖé±íÃæµÄÉúÎï¼ì²â¼¼Êõ£¬°üº¬£º»ùÒòоƬ¡¢µ°°×ÖÊоƬ¡¢¿¹ÌåоƬ¡¢×é֯оƬµÈ¼Ò×å³ÉÔ±¡£ÓÉÓھ߱¸¸ßͨÁ¿¼ì²âµÄÌØÐÔ£¬ÉúÎïоƬ¿ÉÒÔΪÉúÎïҽѧÁìÓòµÄÑо¿ÈËÔ±Ìṩ¹ã·º¶ø¿É¿¿Ñо¿Êý¾Ý¡£
- ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
- ×÷Õߣºk8¿·¢(Öйú)
- À´Ô´£º
- ·¢²¼Ê±¼ä£º2022-05-23 14:10
- ·ÃÎÊÁ¿£º
ÉúÎïоƬ¼¼ÊõÊÇͨ¹ý»¯Ñ§Å¼ÁªµÄ·½·¨£¬½«ÉúÎï·Ö×Ó£¨¹ÑºËÜÕËá¡¢¿¹Ìå¡¢¿¹Ô¡¢×éÖ¯µÈ£©¸ßÃܶȹÌ×ÅÓÚ¹èƬ»ò´ÅÖé±íÃæµÄÉúÎï¼ì²â¼¼Êõ£¬°üº¬£º»ùÒòоƬ¡¢µ°°×ÖÊоƬ¡¢¿¹ÌåоƬ¡¢×é֯оƬµÈ¼Ò×å³ÉÔ±¡£ÓÉÓھ߱¸¸ßͨÁ¿¼ì²âµÄÌØÐÔ£¬ÉúÎïоƬ¿ÉÒÔΪÉúÎïҽѧÁìÓòµÄÑо¿ÈËÔ±Ìṩ¹ã·º¶ø¿É¿¿Ñо¿Êý¾Ý¡£ÔÚ¸ßÖÊÁ¿µÄÎÄÏ×ÖУ¬ÉúÎïоƬ¼¼ÊõÒѾÊÇ»ñÈ¡È«ÃæÉúÎïÐÅÏ¢µÄÆձ鷽ʽ£¬ÈçºÎºÏÀíÓ¦ÓöàÖÖÉúÎïоƬ¼¼Êõ£¬ÔÚʡʱʡÁ¦µÄͬʱ£¬»ñµÃ¸ßÖÊÁ¿µÄ¿Æѧ³É¹û£¬ÊÇÖÚ¶àÑо¿ÈËÔ±¶¼Ï£ÍûÁ˽âµÄÃØÃÜ¡£
»ªÓ¯ÊÓ½ÇÒÔk8¿·¢(Öйú)ºÏ×÷»ï°é——¸´µ©´óѧÖ×ÁöÑо¿ËùÍõ½¨»ª½ÌÊÚ¿ÎÌâ×é·¢±íµÄһƪJ Clin Invest (IF: 12.282)¾µäÎÄÕÂΪÀý[1]£¬Îª´ó¼Ò½Ò¿ªÕâ¸öÃÕµ×£º
ÈéÏÙ°©£¨BrCa£©ÊÇÑÏÖØÍþвŮÐÔ½¡¿µµÄ×î³£¼ûµÄ¶ñÐÔÖ×Áö£¬ËäȻϵͳµÄÖÎÁÆ·½·¨ÒѾ½µµÍÁË°©Ö¢ÌØÒìÐÔËÀÍöÂÊ£¬µ«ÊÇBrCaÈÔÈ»¾ßÓи߸´·¢ÂʺÍתÒÆÂÊ¡£Òò´Ë£¬Ñо¿BrCa·¢ÉúºÍ½øÕ¹µÄ·Ö×Ó»úÖƶÔBrCaÁÙ´²Õï¶ÏºÍÖÎÁÆÒâÒåÖØ´ó¡£Ö×Áöϸ°ûµÄÉú³¤ÐèÒªºÏÊʵÄÖ×Áö΢»·¾³£¬Ö×Áö΢»·¾³Öлá°üº¬¶àÖÖÀàÐ͵ĻùÖÊϸ°û£¬ÆäÖа©Ïà¹Ø³ÉÏËάϸ°û£¨CAFs£©ÊDzÎÓëÖ×Áö·¢Éú¡¢ÔöÖ³¡¢ÇÖÏ®ºÍÐÂÉúѪ¹ÜÐγɵÄ×î·á¸»µÄϸ°ûÀàÐÍ£¬ËüÖ÷ÒªÓÉ»ùÖÊÖÐÕý³£µÄ³ÉÏËάϸ°û£¨NAFs£©×ª»¯¶øÀ´¡£
λÓÚȾɫÌå17p13.3ÉϵÄת¼Òò×ÓHIC1 (hypermethylated in cancer 1)£¬ÓëÖøÃûÒÖ°©»ùÒòTP53µÄȾɫÌ嶨λ·Ç³£½Ó½ü¡£¶øHIC1ÔÚ¶àÖÖ°©Ö¢×éÖ¯ÖÐÆÕ±é¸ß¶È¼×»ù»¯£¬±íÏÖΪ±í¹ÛÒÅ´«³ÁĬºÍ±í´ïÁ¿µÍ£¬Õâ˵Ã÷HIC1ºÜ¿ÉÄÜÊÇÒ»¸öDZÔÚµÄÒÖ°©»ùÒò¡£
| Step 1£ºTCGAºÍOncomineÊý¾Ý¿âÈ·ÈÏÑо¿Ä¿±ê·Ö×ÓHIC1
ΪȷÈÏHIC1»ùÒòÊÇ·ñÔÚÈéÏÙ°©»¼ÕßÖ×Áö×éÖ¯Öеͱí´ï£¬Ñо¿ÈËÔ±·ÖÎöÁËÁ½¸ö³£ÓõÄÖ×ÁöÊý¾Ý¿â£ºTGCAºÍOncomineÖеÄÊý¾Ý¡£·¢ÏÖTCGAÊý¾Ý¿âÊÕ¼Á½¸öÑо¿°¸ÀýÖУ¬HIC1»ùÒòÔÚÈéÏÙ°©×éÖ¯ÖеÄmRNA±í´ïÁ¿ÏÔÖøµÍÓÚÕý³£×éÖ¯£¬Í¬Ê±·¢Ïָ߷ÖÆÚÈéÏÙ°©×éÖ¯ÖÐHIC1»ùÒò±í´ïÁ¿¸üµÍ£¨Í¼1A£©¡£TGCAÊý¾Ý·´Ó³µÄÏÖÏóµÃµ½ÁËOncomineÊý¾Ý¿âµÄ½øÒ»²½Ó¡Ö¤£¨Í¼1B£©¡£Í¬Ê±£¬ÓÉÓÚÁ½¸öÊý¾Ý¿â¼Ç¼µÄÑо¿°¸Àý¾ßÓдóÁ¿ÁÙ´²Ñù±¾Ëæ·ÃÐÅÏ¢£¬ÀûÓÃKaplan-Meier Plotter·ÖÎö£¬Ñо¿ÈËÔ±»¹Ö¤ÊµÁËHIC1¸ß±í´ïµÄÈéÏÙ°©²¡ÈËÏà¶Ô¾ßÓиüµÍµÄ¸´·¢ÂÊ¡£ÒÔÉÏÁ½¿î¹«¹²Êý¾Ý¿â×ÊÁϵķÖÎö£¬°ïÖúÑо¿ÈËÔ±Ã÷È·ÁËHIC1»ùÒò¾ßÓÐÉîÈëÑо¿µÄ¼ÛÖµ¡£
ͼ1. TCGAºÍOncomineÊý¾Ý¿â·ÖÎöËø¶¨HIC1µÄÑо¿¼ÛÖµ
| Step 2£º¹¹½¨HIC1»ùÒòÇóýСÊóºÍϸ°ûÄ£ÐÍÈ·ÈÏHIC1ÓëÈéÏÙ°©·¢ÉúµÄÖ±½Ó¹Øϵ
ΪÁËÑо¿HIC1ÔÚBrCa½øÕ¹ÖеÄ×÷Óã¬Ñо¿ÈËÔ±¹¹½¨ÁËÌõ¼þÐÔÇóýHIC1»ùÒòµÄCre-LoxСÊó£¬Í¨¹ý½«±í´ïWap-CreµÄСÊóÓëHic1fl/flСÊóÔÓ£¬»ñµÃ½öÔÚÈéÏÙÉÏƤϸ°ûÌØÒìÇóýHIC1»ùÒòµÄCre-positive Hic1fl/flСÊ󣬲¢½«Cre-negative Hic1fl/fl×÷Ϊ¶ÔÕÕ×éÃüÃûΪHic1+/+×é¡£
ͼ2. ÌåÄÚ-ÌåÍâʵÑéÈ·Ö¤HIC1»ùÒòÓëÈéÏÙ°©·¢ÉúµÄÖ±½Ó¹Øϵ
Ïà±È½Ï¶ÔÕÕ×飬HIC1»ùÒòÇóýºó£¬ëÙÖ¬ºìȾɫºóµç¾µ¹Û²ìÏÔʾ£¬Ð¡ÊóÈéÏÙµ¼¹ÜÊ÷·¢ÉúÁËÏÔÖø¸Ä±ä£¨Í¼2A£©¡£ÒÑÓÐÑо¿±íÃ÷HIC1ȱʧ¿ÉÄÜÒýÆð»ùÖÊϸ°û£¨NAFs£©·ÖÃÚÌØÊâÒò×Ó´Ó¶øµ÷½Ú»ùÖÊ΢»·¾³¡£Ñо¿ÈËÔ±½øÐÐÁËСÊóÈéÏÙ×éÖ¯ÃâÒß×黯·ÖÎö£¬½á¹ûÏÔʾHIC1ȱʧСÊóµÄÈéÏÙ»ùÖÊÖа©Ïà¹Ø³ÉÏËάϸ°û£¨CAFs£©´ú±íµÄ±êÖ¾Îïµ°°×α-SMA£¨α-smooth muscle actin£©³öÏÖÁËÇ¿ÑôÐÔÐźţ¬ËµÃ÷NAFs¿ÉÄܱ»ÏÔÖø»î»¯×ª±äΪCAFs£¨Í¼2B£©¡£
Ñо¿ÈËÔ±Ïë½øÒ»²½ÔÚÌåÍâÑéÖ¤ÕâÒ»·¢ÏÖ£¬ÓÃCRISPR-Cas9¼¼Êõ»ñµÃÁËHIC1ȱʧµÄÁ½ÖÖ¹ÜÇ»BrCaϸ°ûϵ£¬MCF7sgHIC1ºÍT47DsgHIC1¡£Ñо¿ÈËÔ±½«MCF7CtrlMCF7sgHIC1ºÍT47DCtrlT47DsgHIC1·Ö±ðÓëÔ´úNAFsͨ¹ýTranswellСÊÒ½øÐй²ÅàÑø£¨Í¼2C£©¡£ÀûÓÃWestern blotµÈ¼¼Êõ¼ì²âMCF7sgHIC1 T47DsgHIC1¹²ÅàÑøµÄÔ´úNAFsÖÐα-SMAµÄ±í´ïÁ¿£¬½á¹ûÏÔʾΪα-SMA±í´ïÏÔÖøÔö¼Ó£¬¼´Ö¤Ã÷NAFsȷʵ¿ÉÒÔ±»BrCaϸ°ûͨ¹ý¼ä½ÓµÄ·½Ê½±»»î»¯³ÉΪ CAFs£¨Í¼2D£©¡£
| Step 3£º»ùÒò±í´ïÆ×оƬ·¢ÏÖCAFs»î»¯Òò×ÓCXCL14
ÓÉÓÚÇ°ÆÚʵÑé֤ʵ£¬HIC1ȱʧµÄBrCaϸ°ûϵºÍÔ´úNAFsϸ°û¹²ÅàÑø£¬»á´Ù½øNAFsÏòCAFsϸ°ûת»¯£¬¶øÇÒÊÇͨ¹ý¼ä½ÓµÄ·½Ê½Íê³ÉµÄ¡£ÄÇô£¬×îÓпÉÄܵÄÇé¿öÊÇBrCaϸ°ûÅàÑøÉÏÇåÖеķÖÃÚµ°°×´©¹ýTranswellСÊҵķָôĤ£¬µ½´ïNAFsÅàÑø²ãÖУ¬ÓÕµ¼Æä»î»¯³ÉΪCAFsϸ°û£¨Î¢»·¾³¸ÅÄ¡£
ͼ3 È·¶¨ÒÖÖÆÐÔת¼Òò×ÓHIC1µÄÏÂÓΰлùÒòCXCL14
ÔÚ2014Ä꣬Íõ½¨»ª½ÌÊÚ¿ÎÌâ×é·¢±íÔÚCancer ResÉϵÄÒ»¸öÑо¿¹¤×÷ÖÐ[2]£¬ÀûÓûùÒò±í´ïÆ×оƬµÄ·½Ê½ÏµÍ³É¸Ñ¡Á˹ý±í´ïHIC1µÄBrCaϸ°ûϵMDA-MB-231ºÍÇóýHIC1µÄBrCaϸ°ûϵHBL-100Öеıí´ïÆױ仯£¬·¢ÏÖÁËһϵÁÐϸ°ûÒò×ÓµÄmRNA±í´ïˮƽÊܵ½ÁËHIC1µÄµ÷¿Ø¡£ÆäÖÐÇ÷»¯Òò×ÓCXCL14£¨(C-X-Cmotif 14£©±í´ïÔÚHIC1ÇóýµÄHBL-100ϸ°ûϵÖÐÉϵ÷×îΪÏÔÖø£¨Í¼3A£©¡£ÔÚ±¾Ñо¿ÖУ¬Ñо¿ÈËÔ±ºÏÀíÀûÓÃÇ°ÆÚ¹¤×÷»ù´¡ÖеÄоƬÊý¾Ý£¬½«CXCL14Ëø¶¨ÎªHIC1µÄÖ÷Òªµ÷¿Ø°Ð»ùÒò¡£Í¬Ê±£¬ÔÚMCF7sgHIC1¡¢T47DsgHIC1ºÍMDA-MB-231HIC1ϸ°ûϵÖУ¬ÀûÓÃRT-PCRºÍÃâÒß×黯ʵÑé֤ʵÁËCXCL14µÄmRNAºÍµ°°×±í´ïȷʵ¾ùÊܵ½ÁËHIC1µÄ¸ºÏòµ÷¿Ø¡£
ÓÉÓÚHIC1ÊÇÒ»¸öÒÖÖÆÐÔת¼Òò×Ó£¬¿ÉÒÔÖ±½Ó½áºÏµ½°Ð»ùÒòµÄÆô¶¯×ÓÇøÓò¡£Îª½øÒ»²½È·¶¨CXCL14ÊÇ·ñÊÇHIC1DZÔÚµÄÏÂÓΰб꣬Ñо¿ÈËԱͨ¹ýת¼Òò×ÓÔ¤²â·ÖÎö·¢ÏÖCXCL14»ùÒòÆô¶¯×ÓÇøÓòÓÐ11¸öHIC1½áºÏλµã(TGCC/GGCA)£¬²¢¹¹½¨Á˸²¸ÇCXCL14»ùÒò5’Æô¶¯×ÓÇøÓò–2000~ +136Çø¶ÎµÄÓ«¹âËØø±¨¸æÖÊÁ££¨Í¼3B£©¡£½«ÖÊÁ£×ªÈë293TºÍMCF7ϸ°ûϵÖУ¬¾ù·¢ÏÖHIC1¿É½áºÏCXCL14»ùÒòÆô¶¯×ÓÇøÓòÖеĖ2000~ +136¡¢ -726~ +136ºÍ-276~ +136Çø¶Î£¬²¢ÏÔÖøÒÖÖÆCXCL14»ùÒòµÄ±í´ï£¨Í¼3C£©¡£Ëæºó£¬Chip-PCRʵÑéҲ֤ʵÁËHIC1¿ÉÒÔÌØÒìÐÔ½áºÏÓÚ CXCL14 Æô¶¯×ÓÐòÁУ¨Í¼3D£©¡£ÉÏÊö½á¹ûÃ÷ȷ֤ʵÁËHIC1¶ÔCXCL14»ùÒòµÄ¸ºÏòµ÷¿Ø×÷Óá£
| Step 4£º20KÈËÀ൰°×ÖÊ×éоƬËø¶¨CXCL14µÄÊÜÌåGRP85
ÄÇô£¬BrCaϸ°û·ÖÃÚ³öµÄCXCL14ÓÖÊÇÈçºÎÓÕµ¼NAFs»î»¯³ÉΪCAFsϸ°ûµÄÄØ£¿
ϸ°ûÒò×Ó£¨Ç÷»¯Òò×ÓÒ²ÊÇϸ°ûÒò×ÓµÄÒ»ÖÖ£©ÊÇϸ°û¼äͨѶµÄÖØÒª¹¤¾ß£¬ÊÇ΢»·¾³Ñо¿µÄÖØÒª°Ð±ê¡£Ñо¿ÈËÔ±ÈÏΪBrCaϸ°û·ÖÃÚ³öµÄCXCL14ÐèҪͨ¹ý½áºÏNAFsĤÉϵÄÊÜÌ壬½ø¶ø¼¤»îÊÜÌåÏÂÓÎÐźÅͨ·£¬ÒýÆðNAFsÏòCAFsת»¯¡£Ñо¿ÈËÔ±ÀûÓÃbiotin-CXCL14´¦ÀíNAFs£¬¼ÓÈëCy5-streptavidinÃâÒßÓ«¹â£¬µç¾µ¹Û²ì֤ʵÁËCXCL14¶¨Î»ÔÚNAFsϸ°ûĤÉÏ£¨Í¼4A£©¡£Ã÷È·ÁËCXCL14µÄ½áºÏµ°°×£¬¿ÉÄÜÊÇĤÊÜÌå¡£
ͼ4. ·ÖÎöCXCL14µ÷¿ØµÄNAFsÐźÅͨ·
½øÒ»²½£¬Ñо¿ÈËÔ±Óëk8¿·¢(Öйú)ºÏ×÷£¬ÀûÓÃ20KÈËÀ൰°×ÖÊ×éоƬ¼¼Êõ£¬Ñ¸ËÙɸѡÁËbiotin-CXCL14Ö±½Ó½áºÏµ°°×£¬¹²·¢ÏÖоƬÉÏÓÐ32ÖÖĤµ°°×Óëbiotin-CXCL14µ°°×´æÔÚÖ±½Ó½áºÏ¡£ÆäÖÐ7ÖÖ GPCRµ°°×¼°5´Î¿çĤµ°°×±»Öصã¹Ø×¢£¨Í¼4B£©¡£¾¹ýpull-downʵÑ飬Ñо¿ÈËԱ֤ʵÁËGPR85£¨orphan GPCR£©¿ÉÒÔÔÚÌåÄÚ»·¾³ÖÐÓëbiotin-CXCL14½áºÏ£¨Í¼4C£©¡£½øÒ»²½£¬Ñо¿ÈËÔ±¼ì²âÁËCXCL14´¦ÀíºóµÄNAF6ϸ°ûÖеÄCa+Àë×ÓÄÚÁ÷Çé¿ö£¬·¢ÏÖµ±GPR85±»siRNAÒÖÖƺó£¬CXCL14´¦ÀíÒýÆðµÄCa+Àë×ÓÄÚÁ÷¼´Ïûʧ£¨Í¼4D£©£¬ËµÃ÷GPR85ÊÇÏìÓ¦CXCL14ÐźŵÄÖØÒª¹¦ÄÜÊÜÌå¡£
Ç°ÈËÑо¿±íÃ÷£¬ERK1/2¡¢AktÐźÅͨ·µÄ¼¤»îÊÇNAFsÏòCAFsת»¯µÄÖØҪͨ·¡£Ñо¿ÈËÔ±ÓÃWestern blot֤ʵÁË100 ng/mL CXCL14´¦ÀíµÄNAF6ϸ°ûÖУ¬ERK1/2¡¢AktÁ×Ëữ³Éʱ¼äÒÀÀµÐ§Ó¦µØÉϵ÷£¬Í¬Ê±£¬CAFs»î»¯µÄ±êÖ¾Îïµ°°×α-SMAÒ²ÏàÓ¦Éϵ÷¡£È»¶ø£¬µ±GPR85±»siRNAÒÖÖƺó£¬ÉÏÊöÏÖÏó¾ùÖð½¥Ïûʧ£¨Í¼4E£©¡£ÔÚTranswell¹²ÅàÑøÌåϵÖУ¬MCF7ϸ°ûÒ²¿ÉÒÔÒýÆð¹²ÅàÑøµÄNAF6ϸ°ûÖÐERK1/2¡¢AktÁ×ËữˮƽºÍα-SMAµ°°×±í´ïˮƽµÄÉϵ÷£¬µ±GPR85±»siRNAÒÖÖƺó£¬ÕâЩÏÖÏóÒ²Êܵ½ÁËÒÖÖÆ¡£
| Step 5£ºÏ¸°ûÒò×Ó¿¹ÌåоƬ·¢ÏÖBrCaϸ°ûEMT»¯µÄ¹Ø¼üͨ·CCL17-CCR4
ÉÏÊöÑо¿Ö¤ÊµÁËBrCaϸ°ûͨ¹ý·ÖÃÚ³öµÄCXCL14µ°°×£¬½áºÏÓÚNAFsĤ±íÃæGPR85£¬¼¤»îERK1/2ºÍAktͨ·ÓÕµ¼NAFsת»¯ÎªCAFs£¬ÎªBrCaϸ°û´´ÔìÁ˶ñÐÔÔöÖ³ºÍתÒƵÄ΢»·¾³¡£ÄÇô£¬BrCaÓÖÊÇÔõÑùʵÏÖתÒƵÄÄØ£¿
ͼ5. CAFsϸ°û´Ù½øBrCaϸ°û·¢ÉúEMTת»¯
Ñо¿ÈËÔ±ÖØй¹½¨Á˹²ÅàÑøÌåϵ£¬½«MDA-231-LM2ϸ°û£¨BrCaϸ°û£©Óë³õʼNAF10»ò³õʼCAF10ϸ°û½øÐй²ÅàÑø£¬²¢½øÐÐCXCL14´Ì¼¤¡£µç¾µ¹Û²ì·¢ÏÖÓëCAF10»òÕßCXCL14´¦ÀíºóµÄNAF10¹²ÅàÑøµÄMDA-231-LM2ϸ°û·¢ÉúÁËÏÔÖøµÄתÒÆ£¬´©Í¸ÁËTranswell·Ö¸ôĤ£¨Í¼5A£©¡£ÎªÉ¸Ñ¡CAF10ºÍCXCL14´¦ÀíºóµÄNAF10ϸ°ûÅàÑøÉÏÇåÖеķÖÃÚµ°°×£¬Ñо¿ÈËÔ±¹û¶Ï²ÉÓÃÁ˸ßͨÁ¿µÄϸ°ûÒò×Ó¿¹ÌåоƬ¼¼Êõ£¬¶Ô102ÖÖϸ°ûÒò×Ó½øÐÐÁ˹㷺ɸѡ£¬Ëø¶¨ÁË3ÖÖϸ°ûÒò×ÓÔÚCAF10ºÍCXCL14´¦ÀíºóµÄNAF10ϸ°ûÅàÑøÉÏÇåÖÐÏÔÖøÉϵ÷£¬ÆäÖÐCCL17Éϵ÷×îΪÏÔÖø£¨Í¼5B£©¡£ÓÚÊÇ£¬Ñо¿ÈËÔ±µ¥¶À²ÉÓÃCCL17´¦ÀíMDA-231-LM2ϸ°û4Ììºó£¬Western blotʵÑéÏÔʾ£¬´¦ÀíºóµÄMDA-231-LM2ϸ°ûÖÐEMT£¨ÉÏƤ¼äÖÊת»¯£©µÄ±êÖ¾Îïµ°°×E-CadherinÏÔÖøϵ÷£¬¶øN-CadherinÏÔÖøÉϵ÷£¬ËµÃ÷MDA-231-LM2ϸ°û·¢ÉúÁËEMTÏÖÏ󣬶øÓëÖ®¶ÔÓ¦µÄÊÇAkt/GSK-3βͨ·µÄ¼¤»î£¨Í¼5C£©¡£Ç°ÈËÑо¿È·ÈÏÁËCCL17µÄÊÜÌåΪCCR4£¬Ñо¿ÈËÔ±ÓÃsiRNAÇóýÁËMCF7ºÍMDA-231-LM2ϸ°ûµÄCCR4ºó£¬ÔÙÓÃCCL17½øÐд¦Àí£¬·¢ÏÖÁ½ÖÖBrCaϸ°ûÖеÄEMT±êÖ¾ÎïE-CadherinµÄϵ÷ºÍN-CadherinÉϵ÷ÏÖÏóÊܵ½ÁËÒÖÖÆ£¬Akt/GSK-3βͨ·µÄ¼¤»îÒ²Êܵ½ÁËÒÖÖÆ£¨Í¼5D£©¡£ÉÏÊö½á¹û˵Ã÷ת»¯ºóµÄCAFsϸ°û»áͨ¹ý·ÖÃÚCCL17½øÒ»²½ÓëBrCaϸ°ûĤÉϵÄCCR4ÊÜÌå½áºÏ£¬Í¨¹ý¼¤»îAkt/GSK-3βͨ·£¬´Ù½øBrCaϸ°û·¢ÉúEMT£¬ÊµÏÖÔ¶¶ËתÒÆ¡£
| Step 6£º×é֯оƬÑéÖ¤HIC1-CXCL14-CCL17ÖáÔÚÈéÏÙ°©×ªÒÆÖеÄ×÷ÓÃ
Ϊ½øÒ»²½È·¶¨ÉÏÊö»úÀíÑо¿µÄ½áÂÛÊÇ·ñÄܹ»µÃµ½ÁÙ´²Ñù±¾µÄ֤ʵ£¬Ñо¿ÈËÔ±²ÉÓÃÁ˸ßÃܶÈ×é֯оƬ¼¼Êõ¼ì²âÁË228ÀýBrCa»¼ÕßµÄÉÏƤϸ°ûHIC1¡¢»ùÖÊϸ°ûCXCL14¡¢»ùÖÊϸ°ûCCL17¡¢»ùÖÊϸ°ûGPR85ºÍÉÏƤϸ°ûCCR4µÄµ°°×±í´ï¡£½á¹û·¢ÏÖ£º¶ñÐÔBrCa»¼ÕßÉÏƤϸ°ûºËHIC1ÆÕ±éµÍ±í´ï£¬»ùÖÊCXCL14¡¢CCL17¡¢GPR85ºÍÉÏƤCCR4ÆÕ±é¸ß±í´ï£¨Í¼6A£©¡£ÉÏƤHIC1ºÍ»ùÖÊCXCL14±í´ïˮƽ³Ê¸ºÏà¹Ø£¬»ùÖÊCXCL14ºÍCCL17±í´ïˮƽ³ÊÕýÏà¹Ø£¨Í¼6B£©£¬¸Ã½á¹ûÓëÇ°ÆÚ»úÀíÑо¿½áÂÛÒ»Ö¡£×îÖÕ³¹µ×֤ʵÁËHIC1-CXCL14-CCL17ÖáÔÚÈéÏÙ°©×ªÒÆÖеĺËÐÄ»úÖÆ¡£
ͼ6. ÁÙ´²×éÖ¯Ñù±¾ÖеÄHIC1/CXCL14/CCL17±í´ïÇé¿ö
| С½áÌÖÂÛ
Ö×Áö΢»·¾³ºÍEMTÑо¿ÊǽüÄêÀ´ÉúÎïҽѧÑо¿µÄÈȵ㣬¶øÉúÎïоƬ¼¼ÊõΪ´ú±íµÄ¸ßͨÁ¿×éѧ¼¼Êõ½üÄêÀ´Ò²Å·¢Õ¹¡£ºÜ¶à»ªÓ¯ÊӽǵķÛË¿ÅóÓÑÒªÇóÎÒÃÇÄܹ»ÓÃʵÀýÏêϸÆÊÎö¼¼ÊõºÍ¿ÆѧÁ½ÕßÖ®¼äÈçºÎÄܹ»ÍêÃÀ½áºÏÕâÒ»Ö÷Ì⣿ÖÕÓڵȵ½ÁËÕâÑùһƪ¾µäµÄClin InvestÎÄÏ×Óë´ó¼ÒÒ»Æð·ÖÏí¡£
¸ÃÎÄÏ×ÒÔÈéÏÙ°©µÄתÒÆΪÑо¿Ö÷Ì⣬ͨ¹ý3¸öÊý¾Ý¿â£¨Oncomine¡¢TCGAºÍKaplan-Meier Plotter£©µÄÁªºÏÓ¦Ó÷¢ÏÖÖ×ÁöµÍ±í´ïµÄת¼Òò×ÓHIC1ΪÆðʼ£¬ÏµÍ³ÔËÓÃÁË»ùÒò±í´ïÆ×оƬ¡¢20KÈËÀ൰°×ÖÊ×éоƬ¡¢Ï¸°ûÒò×Ó¿¹ÌåоƬ¡¢×é֯оƬºÍCre-LoxP»ùÒòÇóýСÊóµÈһϵÁÐÑо¿ÊֶΣ¬²ã²ãÉîÈ룬Ϊ´ó¼ÒÖð²½½Ò¿ªÁËBrCaϸ°ûÓëNAFsϸ°û»¥Ïàµ÷¿ØµÄÍêÃÀ»úÀí¡£¼´£ºBrCaϸ°ûÓÉÓÚ¹ý¼×»ù»¯×÷Óõ¼ÖÂÒÖÖÆÐÔת¼Òò×ÓHIC1±í´ïÁ¿½µµÍ£¬½øÒ»²½ÒýÆðÆä¶ÔCXCL14µÄ±í´ïÒÖÖƵĽµµÍ£¬´Ó¶øÔì³ÉBrCaϸ°û´óÁ¿·ÖÃÚCXCL14¡£µ±BrCaϸ°û·ÖÃÚ¹ýÁ¿µÄCXCL14½øÈë×éÖ¯¼ä϶ºó£¬CXCL14»áµ½´¦ÓÎ×ߣ¬ÓëNAFsϸ°ûĤÉϵÄGPR85ÊÜÌå½áºÏ£¬¼¤»îÊÜÌåÏÂÓεÄERK1/2¡¢AktÐźÅͨ·´Ó¶ø»î»¯NAFs£¬Ê¹Æäת±äΪ¾ßÓÐCAFsÌØÐÔµÄϸ°û¡£»ùÖÊÖÐÕâÖÖת»¯¶øÀ´µÄCAFs£¬ÓÖ»á´óÁ¿·ÖÃÚϸ°ûÒò×ÓCCL17£¬ÓÉÓÚÊÇ·ÖÃÚµ°°×£¬CCL17Ò²»áÔÚ×éÖ¯¼ä϶ÖÐÓÎ×ߣ¬×îÖջع鵽BrCaϸ°ûĤÉÏ£¬ÓëÆäĤÉϵÄÊÜÌåCCR4½áºÏ£¬¼¤»îAkt/GSK-3βÐźÅͨ·´Ó¶ø´ÙʹBrCaϸ°û²úÉúEMTÏÖÏ󣨱íÏÖΪE-CadherinµÄϵ÷ºÍN-CadherinÉϵ÷£©£¬½ø¶ø»ñµÃÔ¶¶ËתÒƺÍÇÖÏ®ÄÜÁ¦£¨¼ûͼ7£©¡£¸ÃÑо¿¾¹ýϵͳ·ÖÎö£¬ÑϽ÷ÂÛÖ¤£¬×îÖÕ½Ò¿ªÁËÈéÏÙ°©¶ñÐÔÔöÖ³ºÍתÒƵÄÃ÷ȷDZÔÚ»úÀí£¬ÎªÁÙ´²ÈéÏÙ°©µÄÌØÒìÐÔÕïÁÆÌṩÁËÐÂ˼·¡£
ͼ7 ÈéÏÙ°©×ªÒÆ·Ö×Ó»úÀíͼ
ÏàÐÅ·ÛË¿ÃÇÔÚ¶ÁÍêÕâÑùµÄÎÄÕ£¬ÔÚ¸Ð̾×÷ÕßÖÜÃܵÄÂ߼˼άµÄͬʱ£¬Ò²»á˼¿¼×Ô¼ºµÄÑо¿¹¤×÷ÖÐÊÇ·ñÒ²Äܹ»Óõ½ÕâЩоƬºÍÊý¾Ý¿â¡£´ð°¸Êǿ϶¨µÄ£¬ÎÄÕÂÖÐÉæ¼°µ½µÄËùÓÐ×éѧ¼¼Êõ£¬k8¿·¢(Öйú)¶¼¿ÉÒÔÌṩ·þÎñ£¬»ªÓ¯Êӽǹ«ÖÚºÅÒ²»áΪ´ó¼Ò½«À´ÔÚ·¢±í×Ô¼ºJ Clin InvestÎÄÕµÄʱºòÌṩרҵÉϵİïÖú¡£
| Ïà¹ØÔĶÁ£º
1. ÉϽ»´óÑо¿ÍŶӽÒʾÃ÷ÐÇ»ùÒòPTEN¿¹Ö×ÁöлúÖÆ
2. J Hepatol (IF: 18.946)£ºµÚ¶þ¾üÒ½´óѧÍŶӷ¢ÏÖеÄÒҸβ¡¶¾»ùÒòÑÇÐÍ¿ÉÔ¤²âÖÐÆڸΰ©µÄÔ¤ºó
1. Wang Yingying,Weng Xiaoling,Wang Luoyang et al. HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk.[J] .J. Clin. Invest., 2018, 128: 5235-5250.
2. Cheng Guangcun,Sun Xueqing,Wang Jinglong et al. HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2.[J] .Cancer Res., 2014, 74: 862-72.
µØÖ·£ºÉϺ£ÊÐãÉÐÐÇøÂÌÖÞ»·Â·396Ū5´±4²ã
µç»°£º400-869-2936£¬021-33968791
ÓÊÏ䣺support@wayenbiotech.com
´«Õ棺021-33938792
QQ£º2120485725
Õ½ÂÔºÏ×÷
Õ½ÂÔºÏ×÷
| Full Moon | RayBiotech | CDI | IZON | Bio-Rad | R&D Systems | IsoPlexis | ÄÏÄ£ÉúÎï | Å·Ò×ÉúÎï | ÆäÃ÷ÐÅÏ¢ | ÃÀ¼ªÉúÎï | ÂóÌØ»æÆ× |
Ìرð˵Ã÷£º±¾ÍøËùÓÐÍøÒ³¾ùΪk8¿·¢(Öйú)Ô´´ÐÅÏ¢£¬×ªÔرØÐëÕ÷Çók8¿·¢(Öйú)ͬÒ⣬²¢Í¬Ê±×¢Ã÷±¾ÍøÃû³Æ¼°ÍøÖ·¡£